Advertisement
New Zealand markets closed
  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     
  • NZD/USD

    0.5927
    -0.0007 (-0.12%)
     
  • NZD/EUR

    0.5543
    +0.0002 (+0.04%)
     
  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     
  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     
  • OIL

    82.63
    -0.73 (-0.88%)
     
  • GOLD

    2,338.30
    -3.80 (-0.16%)
     
  • NASDAQ

    17,451.11
    -20.36 (-0.12%)
     
  • FTSE

    8,040.38
    -4.43 (-0.06%)
     
  • Dow Jones

    38,332.98
    -170.71 (-0.44%)
     
  • DAX

    18,088.70
    -48.95 (-0.27%)
     
  • Hang Seng

    17,201.27
    +372.34 (+2.21%)
     
  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     
  • NZD/JPY

    91.8530
    +0.0870 (+0.09%)
     

Jazz Pharmaceuticals: How It’s Positioned before 1Q18

Jazz Pharmaceuticals: How It’s Positioned before 1Q18

In 4Q17, Jazz Pharmaceuticals (JAZZ) generated revenues of $436.4 million compared to $396.6 in 4Q16, which reflected a 10% growth on a YoY (year-over-year) basis and a 6% growth quarter-over-quarter.